<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:epub="http://www.idpf.org/2007/ops" xml:lang="EN">
<head>
<meta name="viewport" content="width=840, height=1080"/>
<meta charset="utf-8"/>
<title>The Morphology of Human Blood Cells</title>
<link href="template.css" type="text/css" rel="stylesheet"/>
</head>
<body>
<div>
<img class="stl_03" src="images/039.jpg" alt=""/>
<div class="layer">
<div class="stl_04 stl_05">
<div style="position:absolute; top:2.6735em; left:36.8773em;"><span class="stl_570 stl_07 stl_42" style="word-spacing:0.0027em;">The Morphology of</span><span class="stl_570 stl_07 stl_42" style="word-spacing:0.0328em;"> Human</span><span class="stl_570 stl_07 stl_42" style="word-spacing:0.0027em;"> Blood</span><span class="stl_570 stl_07 stl_42" style="word-spacing:0.0027em;"> Cells &#160;</span></div>
<div style="position:absolute; top:6.6667em; left:5.25em;"><span class="stl_571 stl_07 stl_21" style="word-spacing:0.057em;">in lymphoblasts.</span><span class="stl_571 stl_07 stl_21" style="word-spacing:0.027em;"> Monocytic</span><span class="stl_571 stl_07 stl_21" style="word-spacing:0.057em;"> esterase stain is positive in</span><span class="stl_571 stl_07 stl_21" style="word-spacing:0.057em;"> M4 &#160;</span></div>
<div style="position:absolute; top:7.6663em; left:5.25em;"><span class="stl_571 stl_07 stl_138" style="word-spacing:0.0238em;">and M5 and negative in lymphoblasts. &#160;</span></div>
<div style="position:absolute; top:6.6653em; left:26.4996em;"><span class="stl_571 stl_07 stl_99" style="word-spacing:0.0332em;">hematopoiesis. However, induction</span><span class="stl_571 stl_07 stl_99" style="word-spacing:0.0632em;"> alone does not</span><span class="stl_571 stl_07 stl_99" style="word-spacing:0.0632em;"> guaran- &#160;</span></div>
<div style="position:absolute; top:7.6649em; left:26.4996em;"><span class="stl_571 stl_07 stl_41" style="word-spacing:0.0288em;">tee the eradication of</span><span class="stl_571 stl_07 stl_41" style="word-spacing:0.0578em;"> leukemia</span><span class="stl_571 stl_07 stl_41" style="word-spacing:0.0288em;"> even in the absence of</span><span class="stl_571 stl_07 stl_41" style="word-spacing:0.0578em;"> mor- &#160;</span></div>
<div style="position:absolute; top:8.6645em; left:26.4996em;"><span class="stl_571 stl_07 stl_58" style="word-spacing:0.3375em;">phologic evidence of</span><span class="stl_571 stl_07 stl_58" style="word-spacing:0.3675em;"> leukemia.</span><span class="stl_571 stl_07 stl_58" style="word-spacing:0.3275em;"> This concept</span><span class="stl_571 stl_07 stl_58" style="word-spacing:0.3275em;"> provides &#160;</span></div>
<div style="position:absolute; top:9.6641em; left:26.4996em;"><span class="stl_571 stl_07 stl_34" style="word-spacing:0.0975em;">rationale for further treatment with chemotherapy usually &#160;</span></div>
<div style="position:absolute; top:10.6637em; left:26.4996em;"><span class="stl_571 stl_07 stl_44" style="word-spacing:0.1051em;">referred to as consolidation.</span><span class="stl_571 stl_07 stl_44" style="word-spacing:0.0741em;"> Bone</span><span class="stl_571 stl_07 stl_44" style="word-spacing:0.1051em;"> marrow</span><span class="stl_571 stl_07 stl_44" style="word-spacing:0.1051em;"> transplantation &#160;</span></div>
<div style="position:absolute; top:11.6633em; left:26.4996em;"><span class="stl_571 stl_07 stl_35" style="word-spacing:0.0987em;">plays an important role in the treatment of</span><span class="stl_571 stl_07 stl_35" style="word-spacing:0.1077em;"> AML.</span><span class="stl_571 stl_07 stl_35" style="word-spacing:0.0687em;"> Patients &#160;</span></div>
<div style="position:absolute; top:12.6629em; left:26.4996em;"><span class="stl_571 stl_07 stl_126" style="word-spacing:0.0237em;">who relapse within a short period after achieving remission &#160;</span></div>
<div style="position:absolute; top:13.6625em; left:26.4996em;"><span class="stl_571 stl_07 stl_44" style="word-spacing:-0.0168em;">and patients with unfavorable prognostic factors are consid- &#160;</span></div>
<div style="position:absolute; top:14.6621em; left:26.4996em;"><span class="stl_571 stl_07 stl_98" style="word-spacing:0.0026em;">ered as candidates for the procedure. Approximately 25% of &#160;</span></div>
<div style="position:absolute; top:15.6617em; left:26.4996em;"><span class="stl_571 stl_07 stl_111" style="word-spacing:0.0936em;">patients with</span><span class="stl_571 stl_07 stl_111" style="word-spacing:0.0736em;"> AML</span><span class="stl_571 stl_07 stl_111" style="word-spacing:0.0936em;"> are expected to be alive more than</span><span class="stl_571 stl_07 stl_111" style="word-spacing:0.0936em;"> five &#160;</span></div>
<div style="position:absolute; top:16.6613em; left:26.4996em;"><span class="stl_571 stl_07 stl_20" style="word-spacing:0.0237em;">years after initial diagnosis. &#160;</span></div>
<div style="position:absolute; top:9.7271em; left:5.25em;"><span class="stl_572 stl_171 stl_36">Therapy &#160;</span></div>
<div style="position:absolute; top:11.5em; left:5.25em;"><span class="stl_571 stl_07 stl_59" style="word-spacing:0.3487em;">Treatment of AML aims at inducing and maintaining &#160;</span></div>
<div style="position:absolute; top:12.4996em; left:5.25em;"><span class="stl_571 stl_07 stl_68" style="word-spacing:0.0581em;">durable remission.</span><span class="stl_571 stl_07 stl_68" style="word-spacing:0.0281em;"> Remission</span><span class="stl_571 stl_07 stl_68" style="word-spacing:0.0581em;"> is defined as circulating</span><span class="stl_571 stl_07 stl_68" style="word-spacing:0.0581em;"> neu- &#160;</span></div>
<div style="position:absolute; top:13.3963em; left:10.6086em;"><span class="stl_573 stl_07 stl_73">9</span></div>
<div style="position:absolute; top:13.3963em; left:17.686em;"><span class="stl_573 stl_07 stl_73">9</span></div>
<div style="position:absolute; top:13.4992em; left:5.25em;"><span class="stl_571 stl_07 stl_61" style="word-spacing:0.0532em;">trophils &gt;1.5x10</span><span class="stl_571 stl_07 stl_61" style="word-spacing:0.1509em;"> /L,</span><span class="stl_571 stl_07 stl_61" style="word-spacing:0.0232em;"> platelets</span><span class="stl_571 stl_07 stl_61" style="word-spacing:0.0532em;"> &gt;100x10</span><span class="stl_571 stl_07 stl_61" style="word-spacing:0.1635em;"> /L,</span><span class="stl_571 stl_07 stl_61" style="word-spacing:0.0232em;"> absence</span><span class="stl_571 stl_07 stl_61" style="word-spacing:0.0532em;"> of</span><span class="stl_571 stl_07 stl_61" style="word-spacing:0.0832em;"> blasts &#160;</span></div>
<div style="position:absolute; top:14.4996em; left:5.2499em;"><span class="stl_571 stl_07 stl_45" style="word-spacing:0.1271em;">in blood,</span><span class="stl_571 stl_07 stl_45" style="word-spacing:0.0971em;"> and</span><span class="stl_571 stl_07 stl_45" style="word-spacing:0.1271em;"> a bone marrow cellularity &gt;20% with</span><span class="stl_571 stl_07 stl_45" style="word-spacing:0.1271em;"> &lt;5% &#160;</span></div>
<div style="position:absolute; top:15.4992em; left:5.2499em;"><span class="stl_571 stl_07 stl_44" style="word-spacing:0.1933em;">blasts. Combination</span><span class="stl_571 stl_07 stl_44" style="word-spacing:0.2243em;"> chemotherapy is always used in</span><span class="stl_571 stl_07 stl_44" style="word-spacing:0.2243em;"> the &#160;</span></div>
<div style="position:absolute; top:16.4988em; left:5.2499em;"><span class="stl_571 stl_07 stl_124" style="word-spacing:-0.0292em;">induction phase of treatment of AML. The goal of induction &#160;</span></div>
<div style="position:absolute; top:17.4984em; left:5.2499em;"><span class="stl_571 stl_07 stl_134" style="word-spacing:0.3458em;">is to reduce the leukemic burden and restore normal &#160;</span></div>
<div style="position:absolute; top:22.9057em; left:9.4588em;"><span class="stl_574 stl_31 stl_575" style="word-spacing:0.0045em;">Myelodysplastic Syndromes &#160;</span></div>
<div style="position:absolute; top:22.2398em; left:6.2533em;"><span class="stl_576 stl_07 stl_73">3</span></div>
<div style="position:absolute; top:22.2398em; left:4.3333em;"><span class="stl_576 stl_07 stl_73">1</span></div>
<div style="position:absolute; top:29em; left:5.25em;"><span class="stl_571 stl_07 stl_577" style="word-spacing:0.2169em;">The term myelodysplastic syndrome (MDS) is used to &#160;</span></div>
<div style="position:absolute; top:29.9996em; left:5.25em;"><span class="stl_571 stl_07 stl_227" style="word-spacing:0.2093em;">describe bilineage or trilineage morphologic dysplastic &#160;</span></div>
<div style="position:absolute; top:30.9992em; left:5.25em;"><span class="stl_571 stl_07 stl_64" style="word-spacing:0.0272em;">changes in the bone marrow.</span><span class="stl_571 stl_07 stl_64" style="word-spacing:-0.0028em;"> By</span><span class="stl_571 stl_07 stl_64" style="word-spacing:0.0272em;"> definition,</span><span class="stl_571 stl_07 stl_64" style="word-spacing:-0.0028em;"> MDS</span><span class="stl_571 stl_07 stl_64" style="word-spacing:0.0272em;"> is a</span><span class="stl_571 stl_07 stl_64" style="word-spacing:0.0272em;"> clonal &#160;</span></div>
<div style="position:absolute; top:31.9988em; left:5.25em;"><span class="stl_571 stl_07 stl_138" style="word-spacing:-0.0139em;">disorder that affects all hematopoietic cell lines. The majori- &#160;</span></div>
<div style="position:absolute; top:32.9984em; left:5.25em;"><span class="stl_571 stl_07 stl_124" style="word-spacing:-0.0264em;">ty of patients with MDS are destined to transform into acute &#160;</span></div>
<div style="position:absolute; top:33.998em; left:5.25em;"><span class="stl_571 stl_07 stl_54" style="word-spacing:0.1967em;">leukemia. Myelodysplastic</span><span class="stl_571 stl_07 stl_54" style="word-spacing:0.2267em;"> syndromes appearing</span><span class="stl_571 stl_07 stl_54" style="word-spacing:0.2267em;"> without &#160;</span></div>
<div style="position:absolute; top:34.9976em; left:5.25em;"><span class="stl_571 stl_07 stl_37" style="word-spacing:0.007em;">obvious explanation or cause are called </span><span class="stl_578 stl_07 stl_37" style="word-spacing:0.007em;">de novo</span><span class="stl_571 stl_07 stl_37" style="word-spacing:0.007em;">, while those &#160;</span></div>
<div style="position:absolute; top:35.9972em; left:5.25em;"><span class="stl_571 stl_07 stl_579" style="word-spacing:0.1979em;">developing after exposure to chemicals,</span><span class="stl_571 stl_07 stl_579" style="word-spacing:0.1679em;"> radiation,</span><span class="stl_571 stl_07 stl_579" style="word-spacing:0.1679em;"> or &#160;</span></div>
<div style="position:absolute; top:36.9968em; left:5.25em;"><span class="stl_571 stl_07 stl_36" style="word-spacing:-0.0001em;">chemotherapeutic agents are called secondary MDS. &#160;</span></div>
<div style="position:absolute; top:28.998em; left:26.4999em;"><span class="stl_571 stl_07 stl_39" style="word-spacing:-0.0556em;">Single or complex cytogenetic abnormalities are found in the &#160;</span></div>
<div style="position:absolute; top:29.9976em; left:26.4999em;"><span class="stl_571 stl_07 stl_42" style="word-spacing:0.0018em;">majority of</span><span class="stl_571 stl_07 stl_42" style="word-spacing:0.0308em;"> patients</span><span class="stl_571 stl_07 stl_42" style="word-spacing:-0.0082em;"> with MDS. They</span><span class="stl_571 stl_07 stl_42" style="word-spacing:0.0018em;"> often involve</span><span class="stl_571 stl_07 stl_42" style="word-spacing:0.0018em;"> chromo- &#160;</span></div>
<div style="position:absolute; top:30.9972em; left:26.4999em;"><span class="stl_571 stl_07 stl_580" style="word-spacing:-0.1015em;">somes 5, 7, and 8 alone or in combination with other defects. &#160;</span></div>
<div style="position:absolute; top:33.0605em; left:26.5em;"><span class="stl_572 stl_171 stl_360">Treatment &#160;</span></div>
<div style="position:absolute; top:34.8333em; left:26.5em;"><span class="stl_571 stl_07 stl_133" style="word-spacing:0.07em;">Treatment of</span><span class="stl_571 stl_07 stl_133" style="word-spacing:0.099em;"> MDS</span><span class="stl_571 stl_07 stl_133" style="word-spacing:0.07em;"> includes support with red blood cell</span><span class="stl_571 stl_07 stl_133" style="word-spacing:0.07em;"> or &#160;</span></div>
<div style="position:absolute; top:35.8329em; left:26.5em;"><span class="stl_571 stl_07 stl_34" style="word-spacing:0.0737em;">platelet transfusions for patients with refractory anemia or &#160;</span></div>
<div style="position:absolute; top:36.8325em; left:26.5em;"><span class="stl_571 stl_07 stl_68" style="word-spacing:0.0199em;">thrombocytopenia. Aggressive</span><span class="stl_571 stl_07 stl_68" style="word-spacing:0.0689em;"> antibiotic therapy should</span><span class="stl_571 stl_07 stl_68" style="word-spacing:0.0689em;"> be &#160;</span></div>
<div style="position:absolute; top:37.8321em; left:26.5em;"><span class="stl_571 stl_07 stl_99" style="word-spacing:0.2353em;">administered to patients with neutropenic fever.</span><span class="stl_571 stl_07 stl_99" style="word-spacing:0.2053em;"> Growth &#160;</span></div>
<div style="position:absolute; top:38.8317em; left:26.5em;"><span class="stl_571 stl_07 stl_87" style="word-spacing:0.2701em;">factors to maintain appropriate levels of</span><span class="stl_571 stl_07 stl_87" style="word-spacing:0.2991em;"> red</span><span class="stl_571 stl_07 stl_87" style="word-spacing:0.27em;"> cells,</span><span class="stl_571 stl_07 stl_87" style="word-spacing:0.2401em;"> neu- &#160;</span></div>
<div style="position:absolute; top:39.8313em; left:26.5em;"><span class="stl_571 stl_07 stl_187" style="word-spacing:-0.0171em;">trophils, and platelets have recently become available to help &#160;</span></div>
<div style="position:absolute; top:40.8309em; left:26.5em;"><span class="stl_571 stl_07 stl_111" style="word-spacing:0.1446em;">support patients with MDS.</span><span class="stl_571 stl_07 stl_111" style="word-spacing:0.1146em;"> These</span><span class="stl_571 stl_07 stl_111" style="word-spacing:0.1446em;"> measures,</span><span class="stl_571 stl_07 stl_111" style="word-spacing:0.1146em;"> however,</span><span class="stl_571 stl_07 stl_111" style="word-spacing:0.1146em;"> do &#160;</span></div>
<div style="position:absolute; top:41.8305em; left:26.5em;"><span class="stl_571 stl_07 stl_37" style="word-spacing:0.0083em;">not alter the course of</span><span class="stl_571 stl_07 stl_37" style="word-spacing:0.0383em;"> these</span><span class="stl_571 stl_07 stl_37" style="word-spacing:0.0083em;"> patients but provide</span><span class="stl_571 stl_07 stl_37" style="word-spacing:0.0083em;"> temporary &#160;</span></div>
<div style="position:absolute; top:42.8301em; left:26.5em;"><span class="stl_571 stl_07 stl_18" style="word-spacing:0.1311em;">control of</span><span class="stl_571 stl_07 stl_18" style="word-spacing:0.1611em;"> the</span><span class="stl_571 stl_07 stl_18" style="word-spacing:0.1311em;"> symptoms.</span><span class="stl_571 stl_07 stl_18" style="word-spacing:0.1011em;"> Presently, only</span><span class="stl_571 stl_07 stl_18" style="word-spacing:0.1311em;"> patients</span><span class="stl_571 stl_07 stl_18" style="word-spacing:0.1311em;"> younger &#160;</span></div>
<div style="position:absolute; top:43.8297em; left:26.5em;"><span class="stl_571 stl_07 stl_67" style="word-spacing:0.0992em;">than 55 years of</span><span class="stl_571 stl_07 stl_67" style="word-spacing:0.1282em;"> age</span><span class="stl_571 stl_07 stl_67" style="word-spacing:0.0992em;"> can potentially be cured by</span><span class="stl_571 stl_07 stl_67" style="word-spacing:0.0992em;"> matched- &#160;</span></div>
<div style="position:absolute; top:44.8293em; left:26.5em;"><span class="stl_571 stl_07 stl_37" style="word-spacing:0.0233em;">sibling bone marrow transplantation. &#160;</span></div>
<div style="position:absolute; top:39.0605em; left:5.25em;"><span class="stl_572 stl_171 stl_67" style="word-spacing:0.0221em;">Presentation of</span><span class="stl_572 stl_171 stl_67" style="word-spacing:0.0521em;"> MDS &#160;</span></div>
<div style="position:absolute; top:40.8333em; left:5.25em;"><span class="stl_571 stl_07 stl_37" style="word-spacing:0.1391em;">The majority of</span><span class="stl_571 stl_07 stl_37" style="word-spacing:0.1681em;"> patients</span><span class="stl_571 stl_07 stl_37" style="word-spacing:0.1391em;"> affected with MDS are above</span><span class="stl_571 stl_07 stl_37" style="word-spacing:0.1391em;"> 60 &#160;</span></div>
<div style="position:absolute; top:41.8329em; left:5.25em;"><span class="stl_571 stl_07 stl_15" style="word-spacing:-0.0204em;">years of age. Patients usually present with refractory anemia, &#160;</span></div>
<div style="position:absolute; top:42.8325em; left:5.25em;"><span class="stl_571 stl_07 stl_581" style="word-spacing:0.1855em;">fatigue, and</span><span class="stl_571 stl_07 stl_581" style="word-spacing:0.2145em;"> fever secondary to neutropenic</span><span class="stl_571 stl_07 stl_581" style="word-spacing:0.2145em;"> infections. &#160;</span></div>
<div style="position:absolute; top:43.8321em; left:5.25em;"><span class="stl_571 stl_07 stl_37" style="word-spacing:0.1152em;">Thrombocytopenia is common in patients with MDS and &#160;</span></div>
<div style="position:absolute; top:44.8317em; left:5.25em;"><span class="stl_571 stl_07 stl_87" style="word-spacing:0.0371em;">may lead to frequent transfusions to prevent or treat bleed- &#160;</span></div>
<div style="position:absolute; top:45.8313em; left:5.25em;"><span class="stl_571 stl_07 stl_42" style="word-spacing:-0.0452em;">ing episodes. Splenomegaly occurs in approximately 10-20% &#160;</span></div>
<div style="position:absolute; top:46.8309em; left:5.25em;"><span class="stl_571 stl_07 stl_48" style="word-spacing:0.0275em;">of patients</span><span class="stl_571 stl_07 stl_48" style="word-spacing:-0.0025em;"> diagnosed with</span><span class="stl_571 stl_07 stl_48" style="word-spacing:-0.0025em;"> MDS. &#160;</span></div>
<div style="position:absolute; top:46.7342em; left:26.5em;"><span class="stl_582 stl_89 stl_94" style="word-spacing:0.0381em;">Table 6.</span><span class="stl_582 stl_89 stl_94" style="word-spacing:-0.0016em;"> Morphologic</span><span class="stl_582 stl_89 stl_94" style="word-spacing:0.0382em;"> (FAB) Classification</span><span class="stl_582 stl_89 stl_94" style="word-spacing:0.0382em;"> of &#160;</span></div>
<div style="position:absolute; top:47.6507em; left:26.5em;"><span class="stl_582 stl_89 stl_133" style="word-spacing:0.0309em;">Myelodysplastic Syndromes (Plate 56) &#160;</span></div>
<div style="position:absolute; top:49.0017em; left:35.7159em;"><span class="stl_583 stl_166 stl_73">BONE &#160;</span></div>
<div style="position:absolute; top:48.8938em; left:5.25em;"><span class="stl_572 stl_171 stl_393" style="word-spacing:0.0139em;">Laboratory Findings &#160;</span></div>
<div style="position:absolute; top:49.6685em; left:35.2137em;"><span class="stl_583 stl_166 stl_73">MARROW &#160;</span></div>
<div style="position:absolute; top:49.6685em; left:39.1576em;"><span class="stl_583 stl_166 stl_73">BLOOD &#160;</span></div>
<div style="position:absolute; top:49.6685em; left:41.9675em;"><span class="stl_583 stl_166 stl_73">PROGRESSION &#160;</span></div>
<div style="position:absolute; top:50.3351em; left:26.5em;"><span class="stl_583 stl_166 stl_73" style="word-spacing:0.025em;">MDS SUBTYPES &#160;</span></div>
<div style="position:absolute; top:50.3351em; left:34.9228em;"><span class="stl_583 stl_166 stl_73" style="word-spacing:0.025em;">BLASTS (%)</span><span class="stl_583 stl_166 stl_73" style="word-spacing:0.957em;"> BLASTS</span><span class="stl_583 stl_166 stl_73" style="word-spacing:0.025em;"> (%)</span><span class="stl_583 stl_166 stl_73" style="word-spacing:1.183em;"> TO</span><span class="stl_583 stl_166 stl_73" style="word-spacing:0.025em;"> AML</span><span class="stl_583 stl_166 stl_73" style="word-spacing:0.025em;"> (%) &#160;</span></div>
<div style="position:absolute; top:50.6667em; left:5.25em;"><span class="stl_571 stl_07 stl_108" style="word-spacing:0.2213em;">The morphologic abnormalities in MDS include ringed &#160;</span></div>
<div style="position:absolute; top:51.6663em; left:5.25em;"><span class="stl_571 stl_07 stl_20" style="word-spacing:0.0446em;">sideroblasts in the bone marrow of</span><span class="stl_571 stl_07 stl_20" style="word-spacing:0.0736em;"> patients</span><span class="stl_571 stl_07 stl_20" style="word-spacing:0.0446em;"> with</span><span class="stl_571 stl_07 stl_20" style="word-spacing:0.0446em;"> refractory &#160;</span></div>
<div style="position:absolute; top:52.6659em; left:5.25em;"><span class="stl_571 stl_07 stl_24" style="word-spacing:0.0105em;">anemia, bizarre</span><span class="stl_571 stl_07 stl_24" style="word-spacing:0.0405em;"> nuclear shapes,</span><span class="stl_571 stl_07 stl_24" style="word-spacing:0.0105em;"> frequent</span><span class="stl_571 stl_07 stl_24" style="word-spacing:0.0405em;"> mitosis,</span><span class="stl_571 stl_07 stl_24" style="word-spacing:0.0105em;"> and</span><span class="stl_571 stl_07 stl_24" style="word-spacing:0.0405em;"> inter- &#160;</span></div>
<div style="position:absolute; top:53.6655em; left:5.25em;"><span class="stl_571 stl_07 stl_126" style="word-spacing:-0.0012em;">nuclear bridging (</span><span class="stl_584 stl_07 stl_124" style="word-spacing:-0.0014em;">PLATE</span><span class="stl_571 stl_07 stl_126" style="word-spacing:0.0394em;"> 56).</span><span class="stl_571 stl_07 stl_126" style="word-spacing:-0.0302em;"> Hypogranulated</span><span class="stl_571 stl_07 stl_126" style="word-spacing:0.0008em;"> granulocytes &#160;</span></div>
<div style="position:absolute; top:54.6663em; left:5.2503em;"><span class="stl_571 stl_07 stl_36" style="word-spacing:0.1611em;">and hyposegmented leukocytes with abnormal chromatin &#160;</span></div>
<div style="position:absolute; top:55.6659em; left:5.2503em;"><span class="stl_571 stl_07 stl_219" style="word-spacing:0.1272em;">condensation (pseudo-Pelger-Huët) are common observa- &#160;</span></div>
<div style="position:absolute; top:56.6655em; left:5.2503em;"><span class="stl_571 stl_07 stl_138" style="word-spacing:-0.0083em;">tions (</span><span class="stl_584 stl_07 stl_41" style="word-spacing:-0.009em;">PLATE</span><span class="stl_571 stl_07 stl_138" style="word-spacing:-0.0064em;"> 56). Micromegakaryocytes and other</span><span class="stl_571 stl_07 stl_138" style="word-spacing:-0.0064em;"> dysmor- &#160;</span></div>
<div style="position:absolute; top:57.6663em; left:5.2502em;"><span class="stl_571 stl_07 stl_127" style="word-spacing:0.1162em;">phic megakaryocytes can be seen in all types of</span><span class="stl_571 stl_07 stl_127" style="word-spacing:0.1452em;"> MDS</span><span class="stl_571 stl_07 stl_127" style="word-spacing:0.1162em;"> but &#160;</span></div>
<div style="position:absolute; top:58.6659em; left:5.2502em;"><span class="stl_571 stl_07 stl_36" style="word-spacing:-0.046em;">especially the 5q-syndrome. Because of the variation in mor- &#160;</span></div>
<div style="position:absolute; top:59.6655em; left:5.2502em;"><span class="stl_571 stl_07 stl_240" style="word-spacing:0.2202em;">phologic appearances,</span><span class="stl_571 stl_07 stl_240" style="word-spacing:0.1902em;"> risks</span><span class="stl_571 stl_07 stl_240" style="word-spacing:0.2202em;"> for transformation to</span><span class="stl_571 stl_07 stl_240" style="word-spacing:0.2202em;"> acute &#160;</span></div>
<div style="position:absolute; top:60.6651em; left:5.2502em;"><span class="stl_571 stl_07 stl_102" style="word-spacing:0.2011em;">leukemia, and</span><span class="stl_571 stl_07 stl_102" style="word-spacing:0.2301em;"> prognosis,</span><span class="stl_571 stl_07 stl_102" style="word-spacing:0.2011em;"> the</span><span class="stl_571 stl_07 stl_102" style="word-spacing:0.2301em;"> myelodysplastic</span><span class="stl_571 stl_07 stl_102" style="word-spacing:0.2301em;"> syndromes &#160;</span></div>
<div style="position:absolute; top:61.6647em; left:5.2502em;"><span class="stl_571 stl_07 stl_173" style="word-spacing:0.0562em;">have been classified into five categories depicted in Table 6. &#160;</span></div>
<div style="position:absolute; top:51.3786em; left:26.5em;"><span class="stl_585 stl_169 stl_132" style="word-spacing:0.023em;">Refractory anemia (RA) &#160;</span></div>
<div style="position:absolute; top:51.3673em; left:36.1348em;"><span class="stl_586 stl_148 stl_37">≤</span><span class="stl_585 stl_169 stl_37">5 &#160;</span></div>
<div style="position:absolute; top:52.7116em; left:36.1107em;"><span class="stl_587 stl_89 stl_68">&lt;</span><span class="stl_585 stl_169 stl_68">5 &#160;</span></div>
<div style="position:absolute; top:51.3673em; left:39.2224em;"><span class="stl_586 stl_148 stl_37">≤</span><span class="stl_585 stl_169 stl_37">1 &#160;</span></div>
<div style="position:absolute; top:52.7116em; left:39.1983em;"><span class="stl_587 stl_89 stl_68">&lt;</span><span class="stl_585 stl_169 stl_68">1 &#160;</span></div>
<div style="position:absolute; top:51.3786em; left:43.0212em;"><span class="stl_585 stl_169 stl_73">8</span></div>
<div style="position:absolute; top:52.7116em; left:26.5em;"><span class="stl_585 stl_169 stl_132" style="word-spacing:0.023em;">Refractory anemia with &#160;</span></div>
<div style="position:absolute; top:53.7118em; left:26.5em;"><span class="stl_585 stl_169 stl_36" style="word-spacing:0.025em;">ringed sideroblasts (RARS) &#160;</span></div>
<div style="position:absolute; top:52.7116em; left:42.6698em;"><span class="stl_585 stl_169 stl_36">12 &#160;</span></div>
<div style="position:absolute; top:55.0449em; left:26.5em;"><span class="stl_585 stl_169 stl_132" style="word-spacing:0.023em;">Refractory anemia with &#160;</span></div>
<div style="position:absolute; top:56.0451em; left:26.5em;"><span class="stl_585 stl_169 stl_36" style="word-spacing:0.025em;">excess blasts (RAEB) &#160;</span></div>
<div style="position:absolute; top:55.0449em; left:35.4689em;"><span class="stl_585 stl_169 stl_36">5–20 &#160;</span></div>
<div style="position:absolute; top:57.3781em; left:35.76em;"><span class="stl_587 stl_89 stl_21">&lt;</span><span class="stl_585 stl_169 stl_21">20 &#160;</span></div>
<div style="position:absolute; top:55.0337em; left:39.2224em;"><span class="stl_586 stl_148 stl_37">≤</span><span class="stl_585 stl_169 stl_37">5 &#160;</span></div>
<div style="position:absolute; top:57.3781em; left:39.1976em;"><span class="stl_587 stl_89 stl_68">&lt;</span><span class="stl_585 stl_169 stl_68">5 &#160;</span></div>
<div style="position:absolute; top:59.7002em; left:39.2217em;"><span class="stl_586 stl_148 stl_37">≤</span><span class="stl_585 stl_169 stl_37">5 &#160;</span></div>
<div style="position:absolute; top:55.0449em; left:42.6698em;"><span class="stl_585 stl_169 stl_36">44 &#160;</span></div>
<div style="position:absolute; top:57.3781em; left:43.0205em;"><span class="stl_585 stl_169 stl_73">4</span></div>
<div style="position:absolute; top:57.3781em; left:26.5em;"><span class="stl_585 stl_169 stl_36" style="word-spacing:0.025em;">Chronic myelomonocytic &#160;</span></div>
<div style="position:absolute; top:58.3783em; left:26.4993em;"><span class="stl_585 stl_169 stl_36" style="word-spacing:0.025em;">leukemia (CMML) &#160;</span></div>
<div style="position:absolute; top:59.7114em; left:26.4993em;"><span class="stl_585 stl_169 stl_132" style="word-spacing:0.023em;">Refractory anemia with &#160;</span></div>
<div style="position:absolute; top:60.7116em; left:26.4993em;"><span class="stl_585 stl_169 stl_36" style="word-spacing:0.025em;">excess blasts in &#160;</span></div>
<div style="position:absolute; top:61.7117em; left:26.4993em;"><span class="stl_585 stl_169 stl_36" style="word-spacing:0.025em;">transformation (RAEB–T) &#160;</span></div>
<div style="position:absolute; top:59.7114em; left:35.1176em;"><span class="stl_585 stl_169 stl_36">21–30 &#160;</span></div>
<div style="position:absolute; top:59.7114em; left:42.6691em;"><span class="stl_585 stl_169 stl_36">60 &#160;</span></div>
<div style="position:absolute; top:64.0452em; left:47.9161em;"><span class="stl_588 stl_89 stl_210">31 &#160;</span></div>
</div>
</div>
</div>
</body>
</html>
